Topical prevention from high energy visible light-induced pigmentation by 2-mercaptonicotinoyl glycine, but not by ascorbic acid antioxidant: 2 randomized controlled trials

Virginie Piffaut(L'Oréal (France)), Claire Marionnet(L'Oréal (France)), Thierry Passeron(Inserm), Françoise Bernerd(L'Oréal (France)), Romain de Dormael(L'Oréal (France)), Jean-Philippe Belaïdi(L'Oréal (France))
Frontiers in Pharmacology
October 9, 2025
10.3389/fphar.2025.1651068
Cited by 4

Related Papers

Guidelines for the management of vitiligo: the European Dermatology Forum consensus
|British Journal of Dermatology|2012|446
New insights in photoaging, UVA induced damage and skin types
|Experimental Dermatology|2014|376
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
|The Lancet|2023|318
Clinical and Biological Characterization of Skin Pigmentation Diversity and Its Consequences on UV Impact
|International Journal of Molecular Sciences|2018|294
Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo
|Nature Communications|2019|175